


What is claimed :

1. A compound having the molecular structure :

5



wherein R<sub>3</sub> is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety  $-C\equiv CR'$  (R' being hydrogen or C1-C6 lower alkyl);

- 10 wherein R<sub>4</sub> is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein R<sub>17α</sub> is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or R<sub>17α</sub> and R<sub>17β</sub> together are oxygen forming a keto group;


- 15 wherein R<sub>17β</sub> is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or R<sub>17α</sub> and R<sub>17β</sub> together are oxygen forming a keto group;

wherein R<sub>16α</sub> is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;


- 20 wherein R<sub>16β</sub> is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

wherein at least one of R<sub>3</sub> or R<sub>4</sub> is not an hydrogen.

2. The compound selected from the group consisting of :


4-cyano-16 $\alpha$ -methyl-16 $\beta$ -ethyl-1,3,5(10)-estratrien-17 $\beta$ -ol

and

4-cyano-16 $\alpha$ -methyl-16 $\beta$ -ethyl-1,3,5(10)-estratrien-17-one

5

3. A pharmaceutical composition comprising a pharmaceutical acceptable  
 diluent or carrier and a therapeutically acceptable amount of an antiandrogen having  
 10 the molecular structure :



wherein  $R_3$  is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety  $-C\equiv CR'$  ( $R'$  being hydrogen or C1-C6 lower alkyl);

- 5 wherein  $R_4$  is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein  $R_{17\alpha}$  is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or  $R_{17\alpha}$  and  $R_{17\beta}$  together are oxygen forming a keto group;


- 10 wherein  $R_{17\beta}$  is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or  $R_{17\alpha}$  and  $R_{17\beta}$  together are oxygen forming a keto group;

wherein  $R_{16\alpha}$  is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;


- 15 wherein  $R_{16\beta}$  is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

wherein at least one of  $R_3$ , or  $R_4$  is not an hydrogen.

4. A pharmaceutical composition comprising a pharmaceutical acceptable  
20 diluent or carrier and a therapeutically acceptable amount of an antiandrogen  
selected from the group consisting of :

4-cyano-16 $\alpha$ -methyl-16 $\beta$ -ethyl-1,3,5(10)-estratrien-17 $\beta$ -ol

and

4-cyano-16 $\alpha$ -methyl-16 $\beta$ -ethyl-1,3,5(10)-estratrien-17-one

5

5. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia, comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of the compound of claim 1

10

6. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of type 5 17 $\beta$ -hydroxysteroid dehydrogenase

15

7. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5 $\alpha$ -reductase inhibitor.

8. The method of Claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

9. The method of Claim 6, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

10

10. The method of claim 7, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

11. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5 $\alpha$ -reductase inhibitor and an inhibitor of type 5 17 $\beta$ -hydroxysteroid dehydrogenase.

12. The method of Claim 11, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).